MA34326B1 - Formulation de poudre sèche comprenant un médicament antimuscarinique - Google Patents
Formulation de poudre sèche comprenant un médicament antimuscariniqueInfo
- Publication number
- MA34326B1 MA34326B1 MA35474A MA35474A MA34326B1 MA 34326 B1 MA34326 B1 MA 34326B1 MA 35474 A MA35474 A MA 35474A MA 35474 A MA35474 A MA 35474A MA 34326 B1 MA34326 B1 MA 34326B1
- Authority
- MA
- Morocco
- Prior art keywords
- dry powder
- antimuscarinic
- medicine
- powder formulation
- formulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Otolaryngology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention concerne une formulation de poudre sèche adaptée pour l'administration par inhalation au moyen d'un inhalateur de poudre sèche, comprenant un médicament antimuscarinique en tant que substance active. L'invention concerne en outre le procédé pour la préparation de la formulation et son utilisation dans la prévention et/ou le traitement d'une large gamme d'affections comprenant des troubles respiratoires.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10166903 | 2010-06-22 | ||
PCT/EP2011/058804 WO2011160920A1 (fr) | 2010-06-22 | 2011-05-30 | Formulation de poudre sèche comprenant un médicament antimuscarinique |
Publications (1)
Publication Number | Publication Date |
---|---|
MA34326B1 true MA34326B1 (fr) | 2013-06-01 |
Family
ID=42942112
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA35474A MA34326B1 (fr) | 2010-06-22 | 2011-05-30 | Formulation de poudre sèche comprenant un médicament antimuscarinique |
Country Status (22)
Country | Link |
---|---|
US (1) | US20110308519A1 (fr) |
EP (1) | EP2585047A1 (fr) |
JP (1) | JP2013529606A (fr) |
KR (1) | KR20130111967A (fr) |
CN (1) | CN102946868B (fr) |
AR (1) | AR081967A1 (fr) |
AU (1) | AU2011269238A1 (fr) |
BR (1) | BR112012032330A2 (fr) |
CA (1) | CA2803418A1 (fr) |
CL (1) | CL2012003450A1 (fr) |
CO (1) | CO6640319A2 (fr) |
EA (1) | EA201291306A1 (fr) |
MA (1) | MA34326B1 (fr) |
MX (1) | MX2012014541A (fr) |
NZ (1) | NZ604983A (fr) |
PE (1) | PE20130282A1 (fr) |
SG (1) | SG186427A1 (fr) |
TN (1) | TN2012000566A1 (fr) |
TW (1) | TW201204412A (fr) |
UA (1) | UA107499C2 (fr) |
WO (1) | WO2011160920A1 (fr) |
ZA (1) | ZA201209682B (fr) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2154136A1 (fr) | 2008-08-08 | 2010-02-17 | CHIESI FARMACEUTICI S.p.A. | Dérivés de carbone de quinuclidine et ses compositions médicales |
EP2206712A1 (fr) | 2008-12-23 | 2010-07-14 | CHIESI FARMACEUTICI S.p.A. | Dérivés d'amino-ester d'alcaloïde et sa composition médicale |
CN102947298B (zh) * | 2010-06-22 | 2016-03-02 | 奇斯药制品公司 | 生物碱氨基酯衍生物及其药物组合物 |
KR20130087405A (ko) * | 2010-06-22 | 2013-08-06 | 키에시 파르마슈티시 엣스. 피. 에이. | 알칼로이드 아미노에스테르 유도체 및 이의 의약 조성물 |
TR201205852A2 (tr) * | 2011-06-02 | 2012-12-21 | Bi̇lgi̇ç Mahmut | Geliştirilmiş yeni kuru toz formülasyonu. |
TR201105367A2 (tr) * | 2011-06-02 | 2012-12-21 | Bi̇lgi̇ç Mahmut | Akış özellikleri geliştirilmiş bir kuru toz formülasyonu. |
CA2862008A1 (fr) | 2011-12-30 | 2013-07-04 | Chiesi Farmaceutici S.P.A. | Esters de quinuclidine et d'acide 1-azaheterocyclylacetique utilises comme agents antimuscariniques, procede pour leur preparation et compositions medicinales correspondantes |
BR112014025518B1 (pt) | 2012-04-13 | 2022-05-24 | Glaxosmithkline Intellectual Property Development Limited | Partículas agregadas de umeclidinium, vilanterol e fluticasona, composição em pó, inalador, processo para a preparação de partículas agregadas, e, uso de estearato de magnésio em partículas agregadas |
GEP201706672B (en) | 2012-07-05 | 2017-05-25 | Arven Ilac Sanayi Ve Ticaret As | Dry powder inhaler compositions comprising long acting muscorinic antagonists |
US20150290192A1 (en) * | 2012-11-30 | 2015-10-15 | Hoffmann-La Roche Inc. | Inhibitors of bruton's tyrosine kinase |
EP3019153B1 (fr) | 2013-07-11 | 2018-09-05 | Chiesi Farmaceutici S.p.A. | Formulation de poudre sèche comprenant un anticholinergique, un corticostéroïde et un béta-adrénergique pour l'administration par inhalation |
GB201321717D0 (en) * | 2013-12-09 | 2014-01-22 | Pharmachemie Bv | Inhalable Medicaments |
GB201402556D0 (en) | 2014-02-13 | 2014-04-02 | Crystec Ltd | Improvements relating to inhalable particles |
CN114425049A (zh) * | 2016-07-04 | 2022-05-03 | 正大天晴药业集团股份有限公司 | 一种可吸入干粉形式的药物组合物所用的载体的制备方法 |
US11774363B2 (en) * | 2018-08-07 | 2023-10-03 | Norton (Waterford) Limited | Application of raman spectroscopy for the manufacture of inhalation powders |
IT201800007928A1 (it) * | 2018-08-07 | 2020-02-07 | Sofar Spa | Composizione contenente un agente mucolitico per il trattamento di ipersecrezione di muco e dispositivo per il suo dosaggio |
IL300652A (en) | 2020-08-14 | 2023-04-01 | Norton Waterford Ltd | Inhalable formulation of fluticasone propionate and albuterol sulfate |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUP0200185A3 (en) | 1999-03-05 | 2006-07-28 | Chiesi Farma Spa | Improved powdery pharmaceutical compositions for inhalation |
PE20011227A1 (es) | 2000-04-17 | 2002-01-07 | Chiesi Farma Spa | Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros |
US7744855B2 (en) | 2000-06-27 | 2010-06-29 | Vectura Limited | Method of making particles for use in a pharmaceutical composition |
MXPA03005583A (es) | 2000-12-22 | 2004-05-05 | Almirall Prodesfarma Ag | Derivados de carbamato de quinuclidina y su uso como antagonistas m3. |
EA006505B1 (ru) | 2001-12-20 | 2005-12-29 | Лабораториос С.А.Л.В.А.Т.,С.А. | Производные карбамата 1-алкил-1-азониабицикло[2.2.2]октана и их применение в качестве антагонистов мускаринового рецептора |
EP1386630B1 (fr) | 2002-07-31 | 2006-05-17 | CHIESI FARMACEUTICI S.p.A. | Inhalateur de poudre |
MXPA05001903A (es) * | 2002-08-21 | 2005-04-28 | Norton Healthcare Ltd | Composicion para inhalacion. |
TWI363759B (en) * | 2004-04-27 | 2012-05-11 | Glaxo Group Ltd | Muscarinic acetylcholine receptor antagonists |
GB0424284D0 (en) * | 2004-11-02 | 2004-12-01 | Novartis Ag | Organic compounds |
EP1882691A1 (fr) * | 2006-07-26 | 2008-01-30 | CHIESI FARMACEUTICI S.p.A. | Dérivés de quinuclidine comme antagonistes M3 |
GB0811099D0 (en) * | 2008-06-17 | 2008-07-23 | Astrazeneca Ab | New combination 376 |
-
2011
- 2011-05-30 EP EP11724158.8A patent/EP2585047A1/fr not_active Withdrawn
- 2011-05-30 EA EA201291306A patent/EA201291306A1/ru unknown
- 2011-05-30 KR KR1020127033556A patent/KR20130111967A/ko not_active Application Discontinuation
- 2011-05-30 WO PCT/EP2011/058804 patent/WO2011160920A1/fr active Application Filing
- 2011-05-30 BR BR112012032330A patent/BR112012032330A2/pt not_active IP Right Cessation
- 2011-05-30 JP JP2013515798A patent/JP2013529606A/ja not_active Withdrawn
- 2011-05-30 SG SG2012094264A patent/SG186427A1/en unknown
- 2011-05-30 CA CA2803418A patent/CA2803418A1/fr not_active Abandoned
- 2011-05-30 NZ NZ604983A patent/NZ604983A/en not_active IP Right Cessation
- 2011-05-30 CN CN201180030601.1A patent/CN102946868B/zh not_active Expired - Fee Related
- 2011-05-30 UA UAA201214589A patent/UA107499C2/uk unknown
- 2011-05-30 AU AU2011269238A patent/AU2011269238A1/en not_active Abandoned
- 2011-05-30 MA MA35474A patent/MA34326B1/fr unknown
- 2011-05-30 PE PE2012002468A patent/PE20130282A1/es not_active Application Discontinuation
- 2011-05-30 MX MX2012014541A patent/MX2012014541A/es not_active Application Discontinuation
- 2011-06-21 AR ARP110102149A patent/AR081967A1/es unknown
- 2011-06-21 TW TW100121556A patent/TW201204412A/zh unknown
- 2011-06-22 US US13/165,955 patent/US20110308519A1/en not_active Abandoned
-
2012
- 2012-11-30 TN TNP2012000566A patent/TN2012000566A1/en unknown
- 2012-12-06 CL CL2012003450A patent/CL2012003450A1/es unknown
- 2012-12-20 CO CO12230869A patent/CO6640319A2/es active IP Right Grant
- 2012-12-20 ZA ZA2012/09682A patent/ZA201209682B/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP2013529606A (ja) | 2013-07-22 |
TW201204412A (en) | 2012-02-01 |
ZA201209682B (en) | 2014-03-26 |
CL2012003450A1 (es) | 2013-03-15 |
MX2012014541A (es) | 2013-01-29 |
AR081967A1 (es) | 2012-10-31 |
AU2011269238A1 (en) | 2013-01-10 |
PE20130282A1 (es) | 2013-03-25 |
US20110308519A1 (en) | 2011-12-22 |
CN102946868B (zh) | 2014-10-29 |
SG186427A1 (en) | 2013-01-30 |
UA107499C2 (uk) | 2015-01-12 |
BR112012032330A2 (pt) | 2016-11-08 |
NZ604983A (en) | 2014-07-25 |
WO2011160920A1 (fr) | 2011-12-29 |
CA2803418A1 (fr) | 2011-12-29 |
CO6640319A2 (es) | 2013-03-22 |
EA201291306A1 (ru) | 2013-05-30 |
CN102946868A (zh) | 2013-02-27 |
TN2012000566A1 (en) | 2014-04-01 |
KR20130111967A (ko) | 2013-10-11 |
EP2585047A1 (fr) | 2013-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA34326B1 (fr) | Formulation de poudre sèche comprenant un médicament antimuscarinique | |
MA34449B1 (fr) | Formulation de poudre seche comprenant un inhibiteur de phosphodiesterase | |
IL273194B2 (en) | Methods, compounds and preparations for the treatment of parainfluenza virus in patients with a deficiency in the immune system | |
NZ701915A (en) | High-concentration monoclonal antibody formulations | |
MX2011013150A (es) | Composicion farmaceutica para uso en oftalmologia medica y veterinaria. | |
MA35455B1 (fr) | (wo2013045407) dérivés d'estra-1,3,5(10),16-tétraène-3-carboxamide, procédé pour leur fabrication, préparations pharmaceutiques contenant ces substances ainsi que leur utilisation dans la fabrication de médicaments | |
MA33467B1 (fr) | Promédicaments comprenant un conjugué insuline-lieur | |
MA33295B1 (fr) | Nouvelle formulation de diclofénac | |
Zhou et al. | Allicin protects rat cortical neurons against mechanical trauma injury by regulating nitric oxide synthase pathways | |
BR112012019374A2 (pt) | composição farmacêutica, pellet de liberação prolongada, composição farmacêutica oral, método para tratamento de uma doença neurodegenerativa ou um dano ao sistema nervoso em um indivíduo necessitado do mesmo e método para preparação de uma formulação de liberação prolongada de um agente ativo | |
MA33922B1 (fr) | Dérivés hétéroaromatiques de phénylimidazole en tant qu'inhibiteurs de l'enzyme pde10a | |
MA37742B1 (fr) | Dérivés d'oestra-1,3,5 (10), 16-tétraène substitués en position 3, leurs procédés de préparation, préparations pharmaceutiques les contenant, et leur utilisation pour la fabrication de médicaments | |
BR112012030641A2 (pt) | métodos e composições para terapia farmacêutica oral | |
US20180015054A1 (en) | Method of Maintaining the Anti-Depressant Effect of Ketamine With Lithium | |
JP2015524423A5 (fr) | ||
BR112012028047A2 (pt) | sistema de cateter, cateter, método de administração de um agente a um paciente e método para variar uma dosagem de um agente ativo | |
MX2013003523A (es) | Composicion farmaceutica de dosis baja. | |
EA201591768A1 (ru) | Дозированные препараты в качестве модуляторов опиоидного рецептора | |
CN103877005A (zh) | 一种复方奥氮平皮下埋植缓释剂 | |
SA518392177B1 (ar) | نظام إرتواء | |
CN104414968A (zh) | 一种左氧氟沙星单剂量滴眼液及其制备方法 | |
BR112018072177A2 (pt) | composição farmacêutica, recipiente, e, métodos para tratar e prevenir congestão nasal, infecções virais do trato respiratório e/ou inflamação da garganta | |
ES2561380T3 (es) | Agente terapéutico de combinación para el tratamiento de rinitis | |
NZ596881A (en) | Phentermine liquid dosage form | |
US20230372264A1 (en) | Composition for the prevention of infection by sars-cov-2 |